Anti-MRSA agents: under investigation, in the exploratory phase and clinically available

References

• Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible S. aureus bacteremia: a meta-analysis. Clin. Infect. Dis 36, 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Tiemersma EW, Bronzwaer SL, Lyytikainen O et al. Methicillin-resistant Staphylococcus aureus in Europe – 1999–2000. Emerg. Infect. Dis. 10, 1627–1634 (2004).
   Google Scholar
• Jevons M. Celbenin-resistant staphylococci. Br. Med. J. 1, 124–126 (1961).
   Web of Science ®Google Scholar
• Rybak MJ. Therapeutic options in Gram-positive infections. J. Hosp. Infect. 49(Suppl. A), S25–S32 (2001).
   PubMedGoogle Scholar
• Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 358, 1975–1982 (2001).
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis.39, 309–317 (2004).
   PubMed Web of Science ®Google Scholar
• Gales AC, Andrade SS, Sader HS, Jones RN. Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program. J. Chemother. 16, 323–328 (2004).
   PubMed Web of Science ®Google Scholar
• Cordova SP, Heath CH, McGechie DB, Keil AD, Beers MY, Riley TV. Methicillin-resistant S. aureus bacteremia in Western Australian teaching hospitals, 1997–1999: risk factors, outcomes and implications for management. J. Hosp. Infect. 56, 22–28 (2004).
   Google Scholar
• Akoua-Koffi C, Guessennd N, Gbonon V, Faye-Kette H, Dosso M. Methicillin-resistance of S. aureus in Abidjan (1998–2001) a new hospital problem. Med. Mal. Infect. 34, 132–136 (2004).
   PubMedGoogle Scholar
• Seydi M, Sow AI, Soumaré M et al. S. aureus bacteremia in the Dakar Fann University Hospital. Med. Mal. Infect. 34, 210–215 (2004).
   PubMedGoogle Scholar
• Moise PA, Schentag JJ. Vancomycin treatment failures in S. aureus lower respiratory tract infections. Int. J. Antimicrob. Agents 16(Suppl. 1), S31–S34 (2000).
   PubMedGoogle Scholar
• Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulation group II polymorphism in methicillin-resistant S. aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38, 1700–1705 (2004).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Accessory gene regulator (agr) locus in geographically diverse S. aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46, 1492–1502 (2002).
   PubMed Web of Science ®Google Scholar
• Arvidson S, Tegmark K. Regulation of virulence determinants in S. aureus. Int. J. Med. Microb. 291, 159–170 (2001).
   Google Scholar
• Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant S. aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40, 135–136 (1997).
   PubMed Web of Science ®Google Scholar
• Liassine N, Auckenthaler R, Descombes MC, Bes M, Vandenesch F, Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliatine toxin gene. J. Clin. Microb. 42, 825–828 (2004).
   PubMed Web of Science ®Google Scholar
• Noble WC, Virani Z, Cree KG. Co-transfer of vancomycin and other resistant genes from Enterococcus faecalis NCTC 12207 to Staphylococus aureus. FEMS Microb. Lett. 93, 195–198 (1992).
   Web of Science ®Google Scholar
• Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. J. Antimicrob. Chemother. 52, 864–868 (2003).
   PubMed Web of Science ®Google Scholar
• Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbiol. Infect. Dis. 33, 101–112 (1999).
   PubMed Web of Science ®Google Scholar
• Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch. Intern. Med. 160(7), 1001–1004 (2000).
   PubMedGoogle Scholar
• Seaman P, Day M, Russell AD, Ochs D. Susceptibility of capsular S. aureus to some antibiotics, triclosan and cationic biocides. J. Antimicrob. Chemother. 54, 696–697 (2004).
   PubMedGoogle Scholar
• Lambert PA. Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria. J. Appl. Microbiol. 92, S46–S54 (2002).
   PubMed Web of Science ®Google Scholar
• Kerns RJ, Dong SD, Fukuzawa S et al. The role of hydrophobic substituents in the biological activity of glycopeptide antibiotics. J. Am. Chem. Soc. 122, 12608–12609 (2000).
   Google Scholar
• Nagarajan R, Schabel AA, Occolowitz JL, Counter FT, Ott Jl, Felty-Duckworth AM. Synthesis and antibacterial evaluation of N-alkyl vancomycins. J. Antibiotics 42, 63–72 (1988).
   Google Scholar
• Kim RM, Kahne DE, Chapman KT. WO-0069893. Chem. Abstract 134, 5162 (2001).
   Google Scholar
• Nagarajan R. Glycopeptide Antibiotics. Marcel Dekker, NY, USA, 195 (1994).
   Google Scholar
• McAtee JJ, Castle SL, Jin Q, Boger DL. Synthesis and evaluation of vancomycin and vancomycin aglycone analogs that bear modifications in the residue 3 asparagine. Bioorg. Med. Chem. Lett. 12, 1319–1322 (2002).
   PubMed Web of Science ®Google Scholar
• Mu Y, Nodwell M, Pace JL, Shaw JP, Judice JK. Vancomycin disulfide derivatives as antibacterial agents. Bioorg. Med. Chem. Lett. 14, 735–738 (2004).
   PubMed Web of Science ®Google Scholar
• Pavlov AY, Miroshnikova OV, Printsevskaya SS et al. Synthesis and hydrophobic N´-mono and N´,N3-double alkylated erenomycins inhibiting the transglycosylation stage of bacterial cell wall biosynthesis. J. Antibiot. 54, 455–459 (2001).
   PubMedGoogle Scholar
• Goldstein BP, Selva E, Gastaldo L et al. A40926, a new glycopeptide antibiotic with anti-Neisseria activity. Antimicrob. Agents Chemother. 31(12), 1961–1966 (1987).
   PubMedGoogle Scholar
• Panzone G, Ferrari P, Kurz M, Trani A. A novel glycopeptide carrying a 3-oxazolin-5-one ring obtained by intramolecular cyclization. J. Antibiot. 51, 872–879 (1998).
   PubMedGoogle Scholar
• Sillerström E, Wahlund E, Nord CE. In vitro activity of LY 3333328 against anaerobic Gram-positives. J. Chemother. 11, 90–92 (1999).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Carryn S, Snock AS, Mingeot-Leclercq MP, Tulkens PM. LY 3333328 (oritavancin) glycopeptide accumulates in cultured macrophages but is only bacteriostatic towards intracellular Listeria monocytogenes. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, LA, USA (2001).
   Google Scholar
• Kim SJ, Cegelski L, Studelska DR, O'Connor RD, Mehta AK, Schaefer J. The mode of action of vancomycin derivative LY 333328 characterized by REDOR. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy,CA, USA (2002).
   Google Scholar
• Critchley IA, Blosser-Middleton RS, Porter SP et al. Activity of oritavancin against clinical isolates of S. aureus collected from blood specimens in the United States. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002).
   Google Scholar
• Zeckel ML, Preston DA, Allen BS. In vitro activity of LY 333328 and comparative agents against nosocomial Gram-positive pathogens collected in 1997 – global surveillance study. Antimicrob. Agents Chemother. 44, 1370–1374 (2000).
   PubMed Web of Science ®Google Scholar
• Braun DK, Chien Y, Farlow DS, Phillips DS, Wasilewski MM, Zeckel M. Oritavancin (LY333328): a dose-escalation safety and pharmacokinetics study in patients. Eur. Cong. Chemother. Microbiol. Infect. Dis. Istanbul 434 (2001).
   Google Scholar
• Singh MP, Petersen PJ, Weiss WJ, Kong F, Greenstein M. Saccharomicins, novel heptadecaglycoside antibiotics produced by Saccharothrix espanaensis: antibacterial and mechanistic activities. Antimicrob. Agents Chemother. 44, 2154–2159 (2000).
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Weiss WJ, Lenoy EB, He H, Testa RT, Bradford PA. The in vitro activity of a novel cyclic glycopeptide natural product antibiotic AC-98 and comparative antibiotics. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Dushin RG, Wang TZ, Fortier G et al. Synthesis of A-98–6446 a semi-synthetic mannopeptimycin derivative. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002).
   Google Scholar
• Petersen PJ, Labthavikul P, Wang TZ, Dushin RC, Bradford PA. In vitro comparative activity of A-98–6446 a novel semi-synthetic cyclic glycopeptide derivative of the natural product mannopeptimycin α (AC 98–1) and other antimicrobial agents against Gram-positive clinical isolates. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002).
   Google Scholar
• Petersen PJ, Hartman HE, Wang TZ, Dushin RG, Bradford PA. Time-kill kinetics and post-antibiotic effect of AC-98, novel semisynthetic cyclic glycopeptide antibiotic derivative AC-98–6446. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002).
   Google Scholar
• Murphy TM, Lenoy EP, Young M, Weiss WJ. In vivo efficacy and pharmacokinetics of AC-98–6446, a novel glycopeptide in experimental infections. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002).
   Google Scholar
• Tsuji N, Kamigauchi T, Kobayashi M, Terui Y. New glycopeptide antibiotics: II. The isolation and structures chloroorienticins. J. Antibiot. 41, 1506–1510 (1988).
   PubMed Web of Science ®Google Scholar
• Yoshida O, Yasukata T, Sumino Y, Munekage T, Narukawa Y, Nishitani Y. Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B. Bioorg. Med. Chem. Lett. 12, 3027–3031 (2002).
   PubMed Web of Science ®Google Scholar
• Puar MS, Chan TM, Hegde V et al. Sch 40832: a novel thiostrepton from Micromonospora carbonacea. J. Antibiot. 51, 221–224 (1998).
   PubMedGoogle Scholar
• Pavlov AY, Preobrazhenskaya MN, Malabarba A, Ciabatti R, Colombo L. Mono and double modified teicoplanin aglycon derivatives on the amino acid no. 7; structure–activity relationship. J. Antibiot. 51, 73–78 (1998).
   PubMedGoogle Scholar
• Quarta C, Borghi A, Zerilli LF et al. Isolation and structure determination of a novel complex of the teicoplanin family. J. Antibiot. 49, 644–645 (1996).
   PubMedGoogle Scholar
• Jones RN, Biedenbach DJ, Johnson DM, Pfaller MA. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother. 13, 244–254 (2001).
   Google Scholar
• Leighton A, Gottlieb AB, Dorr MB et al. Tolerability, pharmacokinetics and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. 48, 940–945 (2004).
   PubMed Web of Science ®Google Scholar
• Judice JK, Pace JL. Semi-synthetic glycopeptide antibacterials. Bioorg. Med. Chem. Lett. 13, 4165–4168 (2003).
   PubMed Web of Science ®Google Scholar
• Pace JL, Krause K, Johnston D et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 3602–3604 (2003).
   PubMed Web of Science ®Google Scholar
• Preobrazhenskaya MN, Pavlov AY, Maffioli SI, Romano G, Ciabatti R. The synthesis and antibacterial activity of di-alkylated derivatives of glycopeptide DA-40926 and their amide. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002).
   Google Scholar
• Hashizume H, Igarashi M, Hattori S, Hori M, Hamada M, Takeuchi T. Tripropeptins, novel antimicrobial agents produced by Lysobacter spp. I. Taxonomy, isolation and biological activities. J. Antibiot. 54, 1054–1059 (2001).
   PubMed Web of Science ®Google Scholar
• Regueiro-Ren A, Naidu BN, Zheng X et al. Novel semi-synthetic nocathiacin antibiotics: synthesis and antibacterial activity of bis- and mono-O-alkylated derivatives. Bioorg. Med. Chem. Lett. 14, 171–175 (2004).
   PubMedGoogle Scholar
• Naidu BN, Sorenson ME, Hudyma T et al. Synthesis and antibacterial activity of O-substituted nocathiacin I derivatives. Bioorg. Med. Chem. Lett. 14, 3743–3746 (2004).
   PubMedGoogle Scholar
• Vijaya Kumar EK, Kenia J, Mukhopadhyay T, Nadkarni SR. Methylsulfomycin I, a new cyclic peptide antibiotic from a Streptomyces spp. HIL Y-9420704. J. Nat. Prod. 62, 1562–1564 (1999).
   PubMedGoogle Scholar
• Hu Y, Helm JS, Chen L, Ye XY, Walker S. Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to lipid II. J. Am. Chem. Soc. 125, 8736–8737 (2003).
   PubMedGoogle Scholar
• Jabes D, Romano G, Brunati C, Rossi R, Maffioli S, Ciabatti R. In vitro characteristics of VIC-603: a new anti-Gram-positive antibiotic. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2003).
   Google Scholar
• Jabes D, Candiani G, Romano G, Rivas S, Maffioli S, Ciabatti R. Efficacy of VIC-603, a new anti-Gram-positive antibiotic in experimental infection. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2003).
   Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43, 738–744 (1999).
   PubMed Web of Science ®Google Scholar
• Hill J, Finn J, Parr I et al. Novel lipopeptide 1: synthesis and biological activity of ornithine amino amide analogues of daptomycin. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Hill J, Finn J, Parr I et al. Novel lipopeptide 2: synthesis and biological activity of aromatic amide analogs of daptomycin. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Hill J, Siedlecki J, Parr I et al. Synthesis and biological activity of N-acylated ornithine analogs of daptomycin. Bioorg. Med. Chem. Lett. 13, 4187– 4191 .
   PubMedGoogle Scholar
• Hill J, Finn J, Lazarova T et al. Novel lipopeptide 3: synthesis and biological activity of kynurenine modified analogs of daptomycin. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Bemer P, Juvin ME, Bryskier A, Drugeon H. In vivo activities of a new lipopeptide HMR1043 against susceptible and resistant Gram-positive isolates. Antimicrob. Agents Chemother. 47, 3025–3029 (2003).
   PubMedGoogle Scholar
• Borders DB, Lease RA, Jarolmen H et al. Laspartamycin – lipopetide antibiotic with a unique peptide core. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Simon RJ, Curran WV, Leese RA, Borders DB, Koontz MZ, Liu H. Semi-synthetic approaches of laspartomycin analogs. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Kato A, Nakaya S, Suzuki N et al. WAP- 8294 A. A novel anti-MRSA antibiotic produced by Lysobacter spp. J. Am. Chem. Soc. 119, 6680–6681 (1997).
   Web of Science ®Google Scholar
• Kato A, Nakaya S, Kokubo N et al. A new anti-MRSA antibiotic complex WAP-8294A. I. Taxonomy, isolation and biological activities. J. Antibiot. 51, 929–935 (1998).
   PubMed Web of Science ®Google Scholar
• Eid CN, Nicas T, Mullen DL, Loncharich RJ, Paschal JW. Design, synthesis and potentiating activities against methicillin-resistant S. aureus of cyclic analogs of LY 301621. Bioorg. Med. Chem. Lett. 7, 2087–2092 (1997).
   Google Scholar
• Matsumoto N, Momose I, Umekita M et al. Diperamycin, a new antimicrobial antibiotic produced by Streptomyces griseoaurantiacus MK393-AF2. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J. Antibiot. 51, 1087–1092 (1999).
   Google Scholar
• Funabashi Y, Tsubotani S, Koyama K, Katayama N, Harada S. A new anti-MRSA dipetide TAN-1057 A. Tetrahedron 49, 13–28 (1993).
   Web of Science ®Google Scholar
• Katayama N, Fukusumi I, Funabashi Y, Iwahi T, Ono H. TAN-1057 A-D, new antibiotics with potent antibacterial activity against methicillin-resistant Staphylococcus aureus. Taxonomy, fermentation and biological activity. J. Antibiot. 46, 606–613 (1993).
   PubMedGoogle Scholar
• Williams KM, Yuan C, Lee VJ, Chamberland S. Synthesis and antimicrobial evaluation of TAN 1057 A analogs. J. Antibiot. 51, 189–201 (1998).
   PubMedGoogle Scholar
• Limburg E, Beyer D, Gahlmann R. S. aureus resistance to TAN 1057 is mediated by modification of the bacterial ribosome. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002).
   Google Scholar
• Alvarez-Bravo J, Kurata S, Natori S. Novel synthetic antimicrobial peptides effective against methicillin-resistant Staphylococcus aureus. Biochem. J. 302, 535–538 (1994).
   PubMedGoogle Scholar
• Heffron S, Jurnak F. Structure of EF-Tu complex with triazolyl peptide antibiotic determined at 2.35Å resolution: atomic basis for GE 2270 A inhibition of Ef-Tu. Biochemistry 39, 37–45 (2000).
   PubMedGoogle Scholar
• Clough J, Chen S, Gordon EM et al. Combinatorial modification of natural products: synthesis and in vitro analysis of derivatives of thiazole peptide antibiotic GE2270 A: A-ring modifications. Bioorg. Med. Chem. Lett. 13, 3409–3414 (2003).
   PubMedGoogle Scholar
• McNaught JG. On the action of cold and lukewarm tea on Bacillus typhosus. J. Royal Army Med. Corps 7, 372–373 (1906).
   Google Scholar
• Shiota S, Shimizu M, Mizushima T et al. Marked reduction in the minimum inhibitory concentration (MIC) of β-lactam in methicillin-resistant S. aureus produced by epicatechin gallate, an ingredient of green tea (Camellia sinensis). Biol. Pharm. Bull. 32, 1388–1390 (1999).
   Google Scholar
• Yam TS, Shah S, Hamilton Miller JM. Microbiological activity of whole and fractiçnated crude extracts of tea (Camellia sinensis) and of tea components. FEMS Microbiol. Lett. 152, 169–171 (1997).
   PubMed Web of Science ®Google Scholar
• Kubo I, Xiao P, Fujita K. Anti-MRSA activity of alkyl gallates. Bioorg. Med. Chem. Lett. 12, 113–116 (2002).
   PubMed Web of Science ®Google Scholar
• Kusnick C, Jansen R, Liberra K, Lindquist U. Aschochital, a new metabolite from the marine ascomycete Kirschteiniothela maritina. Pharmazie 57, 510–512 (2002).
   PubMed Web of Science ®Google Scholar
• Isnansetyo A, Kamei Y. MC21-A, a bactericidal antibiotic produced by a new marine bacterium, Pseudoalteromonas phenolica spp. nov. O-BC30(T), against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 480–487 (2003).
   PubMed Web of Science ®Google Scholar
• Iinuma M, Tosa H, Tanaka T et al. Antibacterial activity of xanthones from guttiferaeous plants against methicillin-resistant Staphylococcus aureus. J. Pharm. Pharmacol. 48, 861–865 (1996).
   PubMed Web of Science ®Google Scholar
• Ahmad VU, Yasmeen S, Ali Z et al. Taraxacin, a new guaianolide from Taraxacum wallichii. J. Nat. Prod. 63(7), 1010–1011 (2000).
   PubMedGoogle Scholar
• Alpetanga (1983).
   Google Scholar
• Li MKW, Scheuer PJ. A guaianolide pigment from a deep sea gorgonian. Tetrahedron Lett. 25, 2109–2110 (1984).
   Google Scholar
• Kawazoe K, Tsubouchi Y, Abdullah N et al. Sesquiterpenoids from Artemisia gilvescens and an anti-MRSA compound. J. Nat. Prod. 66, 538–539 (2002).
   Google Scholar
• Sato Y, Oketani H, Yamada T et al. A xanthanolide with potent antibacterial activity against methicillin-resistant Staphylococcus aureus. J. Pharm. Pharmacol. 49, 1042–1044 (1997).
   PubMedGoogle Scholar
• Calcul L, Longeon A, Al Mourabit A, Guyot M, Bourguet-Kondracki ML. Novel alkaloids of the aaptamine class from an Indonesian marine sponge of the genus Xestospongia. Tetrahedron 59, 6539–6544 (2003).
   Web of Science ®Google Scholar
• Hibasami H, Midorikawa Y, Gasaluck P et al. Bactericidal effect of 15-deoxyspergualin on Staphylococcus aureus. Chemotherapy (Basel) 35, 202–205 (1991).
   Google Scholar
• Miura S, Iwasaki Y, Tatsuta K. Anti-MRSA activity of 1-(4-chlorophenyl)-3-dichlorophenyl- and 3-trichlorophenyl-2-(1H-imidazol-1-yl)-2-propen-1-one derivatives. J. Antibiot. 47, 1171–1172 (1994).
   PubMedGoogle Scholar
• Sim MM, Ng SB, Buss AD, Crasta SC, Goh KL, Lee SK. Benzylidene rhodanines as novel inhibitors of UDP-N-acetylmuramate/L-alanine ligase. Bioorg. Med. Chem. Lett. 12, 697–699 (2002).
   PubMed Web of Science ®Google Scholar
• Fitzpatrick TB, Killer P, Thomas RM, Jelesarov I, Amrhein N, Macheroux P. Chorismate synthase from the hyperthermophile Thermotoga maritima combines thermostability and increased rigidity with catalytic and spectral properties similar to mesophilic counterparts. J. Biol. Chem. 276(21), 18052–18059 (2001).
   PubMedGoogle Scholar
• Chana S, Chapman S, Charles I et al. Synthesis and SAR of novel inhibitors of the shikimate pathway enzyme dehydroquinate synthase. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Stables J, Chana S, Chapman S et al. In vitro antimicrobial activity of dehydroquinate synthase inhibitors. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Peters SE, Maskell DJ, Charles IG, Stabls JN, Powell KL. In vivo efficacy of inhibitors of the shikimate pathway enzyme dehydroquinate synthase. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Duvold T, Jorgensen A, Andersen NR, Henriksen AS, Dahl Sorensen M, Björkling F. 17S,20S-methanofusidic acid, a new potent semi-synthetic fusidane antibiotic. Bioorg. Med. Chem. Lett. 12, 3569–3572 (2002).
   PubMedGoogle Scholar
• Langley (1962).
   Google Scholar
• Tarantino P, Zhi C, Wright GE, Brown NC. Inhibitors of DNA polymerase III as novel antimicrobial agents against Gram-positive eubacteria. Antimicrob. Agents Chemother. 43, 1982–1987 (1999).
   PubMed Web of Science ®Google Scholar
• Wright GE, Gambino JJ. Quantitative structure–activity relationship of 6-anilinouracils as inhibitors of Bacillus subtilis DNA polymerase III. J. Med. Chem. 27, 181–185 (1984).
   PubMed Web of Science ®Google Scholar
• Cozzarelli NR. The mechanism of action of inhibitors of DNA synthesis. Ann. Rev. Biochem. 46, 641–668 (1977).
   PubMed Web of Science ®Google Scholar
• Wright GE, Brown NC. Inhibitors of Bacillus subtilis DNA polymerase III. Structure–activity relationships of 6-(phenylhydrazino)uracils. J. Med. Chem. 20, 1181–1185 (1977).
   PubMedGoogle Scholar
• Hayakawa Y, Kanamaru N, Shimazu A, Seto H. Lydicamycin, a new antibiotic of a novel skeletal type. I. Taxonomy, fermentation, isolation and biological activity. J. Antibiot. (Tokyo) 44(3), 282–287 (1991).
   PubMedGoogle Scholar
• Hayakawa Y, Kanamaru N, Morisaki N, Furihata K, Seto H. Lydicamycin, a new antibiotic of a novel skeletal type. II. Physico-chemical properties and structure elucidation. J. Antibiot. (Tokyo) 44(3), 288–292 (1991).
   PubMedGoogle Scholar
• Furumai T, Eto K, Sasaki T et al. TPU-0037-A, B, C and D, novel lydicamycin congeners with anti-MRSA activity from Streptomyces platensis TP-A0598. J. Antibiot. 55, 873–880 (2002).
   PubMedGoogle Scholar
• Hoemann MZ, Kumaravel G, Xie RL et al. Potent in vitro methicillin-resistant Staphylococcus aureus activity of 2-(1H-indol-3-yl)quinoline derivatives. Bioorg. Med. Chem. Lett. 10, 2675–2678 (2000).
   PubMedGoogle Scholar
• Hoemann MZ, Xie RL, Rossi RF et al. Potent in vitro methicillin-resistant Staphylococcus aureus activity of 2-(1H-indol-3-yl)tetrahydroquinoline derivatives. Bioorg. Med. Chem. Lett. 12, 129–132 (2002).
   PubMedGoogle Scholar
• Mazmanian SK, Ton-That H, Su K, Schneewind O. An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis. Proc. Natl Acad. Sci. USA 99, 2293–2298 (2002).
   PubMed Web of Science ®Google Scholar
• Kaatz GW, Moudgal VV, Seo SM. Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J. Antimicrob. Chemother. 50, 833–838 (2002).
   PubMed Web of Science ®Google Scholar
• Kaatz GW, Moudgal VV, Seo SM, Hansen JB, Kristiansen JE. Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus. Int. J. Antimicrob. Agents 22, 254–261 (2003).
   PubMed Web of Science ®Google Scholar
• He X, Reeve AM, Desai UR, Kellogg GE, Reynolds KA. 1,2-dithiole-3-ones as potent inhibitors of the bacterial 3-ketoacyl acyl carrier protein synthase III (FabH). Antimicrob. Agents Chemother. 48, 3093–3102 (2004).
   PubMed Web of Science ®Google Scholar
• Look GC, Vacin C, Dias TM et al. The discovery of biaryl acids and amides exhibiting antibacterial activity against Gram-positive bacteria. Bioorg. Med. Chem. Lett. 14, 1423–1426 (2004).
   PubMedGoogle Scholar
• Davis MW, Buechter DD, Schimmel P. Functional dissection of a predicted class-defining motif in a class II tRNA synthetase of unknown structure. Biochemistry 33, 9904–9911 (1994).
   PubMedGoogle Scholar
• Yu XY, Finn J, Hill JM et al. A series of spirocyclic analogues as potent inhibitors of bacterial phenylalanyl-tRNA synthetases. Bioorg. Med. Chem. Lett. 14, 1339–1342 (2004).
   PubMed Web of Science ®Google Scholar
• Yu XY, Finn J, Hill JM et al. A series of heterocyclic inhibitors of phenylalanyl-tRNA synthetases with antibacterial activity. Bioorg. Med. Chem. Lett. 14, 1343–1346 (2004).
   PubMed Web of Science ®Google Scholar
• Hill J, Finn J, Yu X et al. Synthesis and activity of spirocyclic tetrahydrofurans as inhibitors of phenylalanine-t-RNA synthase. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Jarvest RL, Berge JM, Houge-Frydrych CS et al. Interaction of tyrosyl aryl dipeptides with S. aureus tyrosyl tRNA synthetase: inhibition and crystal structure of a complex. Bioorg. Med. Chem. Lett. 9, 2859–2862 (1999).
   PubMed Web of Science ®Google Scholar
• Jarvest RL, Berge JM, Brown MJ et al. Optimization of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent Gram-positive antibacterial activity. Bioorg. Med. Chem. Lett. 13, 665–668 (2003).
   PubMed Web of Science ®Google Scholar
• Jarvest RL, Berge JM, Brown P et al. Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent Gram-positive antibacterial activity. Bioorg. Med. Chem. Lett. 13, 1265–1268 (2003).
   PubMed Web of Science ®Google Scholar
• Jarvest RL, Armstrong SA, Berge JM et al. Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues. Bioorg. Med. Chem. Lett. 14(15), 3937–3941 (2004).
   PubMedGoogle Scholar
• Finn J, Hill J, Ram S et al. Novel antibacterial agents targeting methionyl-t-RNA synthetase, a cheminformatic approach to convert HTS data into quality medicinal chemistry load. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Banwell MG, Crasto CF, Easton CJ et al. Analogues of SB-203207 as inhibitors of tRNA synthetases. Bioorg. Med. Chem. Lett. 10, 2263–2266 (2000).
   PubMed Web of Science ®Google Scholar
• Choudhry AE, Mandichak TL, Broskey JP et al. Inhibitors of pantothenate kinase: novel antibiotics for staphylococcal infections. Antimicrob. Agents Chemother. 47, 2051–2055 (2003).
   PubMed Web of Science ®Google Scholar
• He Y, Yang J, Wu B, Risen L, Swayze EE. Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents. Bioorg. Med. Chem. Lett. 14, 1217–1220 (2004).
   PubMedGoogle Scholar
• Hopmann C, Kurz M, Brönstrup M, Wink J, Le Beller D. Isolation and structure elucidation of vancoresmycin – a new antibiotic from Amycaloptopsis ST 101170. Tetrahedron Lett. 43, 435–438 (2002).
   Google Scholar
• Alcavaz LE, Blanco SE, Puig ON, Thomas T, Ferretti FN. Antibacterial activity of flavonoids against methicillin-resistant S. aureus strain. J. Theor. Biol. 205, 231–240 (2000).
   PubMedGoogle Scholar
• Tanaka H, Sato M, Oh-Uchi T et al. Antibacterial properties of a new isoflavonoid from Erythrina poeppigiana against methicillin-resistant Staphylococcus aureus. Phytomed. 11, 331–337 (2004).
   PubMed Web of Science ®Google Scholar
• Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. 13, 4217–4221 (2003).
   PubMed Web of Science ®Google Scholar
• Dreier J, Ofner C, Stueber D, Danel F, Page MG. Identifying new inhibitors of dihydropteroate synthase from S. aureus. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE Jr, Tenover F. In vitro activities of daptomycin, linezolid, and quinupristin–dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb. Drug Resist. 9, 389–393 (2003).
   Google Scholar
• Bacqué C, Barrière JC, Berthaud N et al. Design, synthesis and in vitro evaluation of XRP 2868, a new oral streptogramin. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Drugeon HB, Juvin ME, Couturier C, Bryskier A. Role of each component (RPR 202868–PI) and RPR 132552–PII in bactericidal synergism of XRP 2868 (a new oral semi synthetic streptogramin) aginst Streptococcus pneumoniae, H. Influenzae and S. aureus. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2003).
   Google Scholar
• Felmingham D, Robbin MJ, Schackcloth J, Denar C, Williams J, Bryskier A. Activity of XRP 2868 against S. pneumoniae, S. aureus, H. influenzae and ‘atypical’ respiratory tract pathogens. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, DC, USA (2004).
   Google Scholar
• Nicolaou KC, Roecker AJ, Barluenga S, Pfefferkorn JA, Cao GQ. Discovery of novel antibacterial agents active against methicillin-resistant S. aureus from combinatorial benzopyran libraries. Chem. Biochem. 2, 460–465 (2001).
   Google Scholar
• Robbins MJ, Shackcloth J, Dencer C, Williams L, Bryskier A, Felmingham D. Comparative in vitro activity of AVE 6971, a novel inhibitor of DNA topoisomerase IV against S. aureus. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, DC, USA (2004).
   Google Scholar
• Musicki B, Periers AM, Laurin P et al. Improved antibacterial activities of coumarin antibiotics bearing 5′,5′-dialkylnoviose: biological activity of RU79115. Bioorg. Med. Chem. Lett. 10, 1695–1699 (2000).
   PubMed Web of Science ®Google Scholar
• Tanitame A, Oyamada Y, Ofuji K et al. Design, synthesis and structure–activity relationship studies of novel indazole analogue as DNA gyrase inhibitors with Gram-positive antibacterial activity. Bioorg. Med. Chem. Lett. 14, 2857–2862 (2004).
   PubMed Web of Science ®Google Scholar
• Tanitame A, Oyamada Y, Ofuji K et al. Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives. J. Med. Chem. 47, 3693–3696 (2004).
   PubMed Web of Science ®Google Scholar
• Lübbers T, Angehrn P, Gmünder H, Herzig S, Kulhanek J. Design, synthesis and structure–activity relationship studies of ATP analogues as DNA gyrase inhibitors. Bioorg. Med. Chem. Lett. 10, 821–826 (2000).
   PubMed Web of Science ®Google Scholar
• Angehrn P, Buchmann S, Funk C et al. New antibacterial agent derived from the DNA gyrase inhibitor, cyclothialidine. J. Med. Chem. 47, 1487–1513 (2004).
   PubMed Web of Science ®Google Scholar
• Sasaki T, Igarashi Y, Saito N, Furumai T. TPU-0031-A and B, new antibiotics of the novobiocin group produced by Streptomyces spp. TP-A0556. J. Antibiot. 54, 441–447 (2001).
   PubMedGoogle Scholar
• Jones RN, Hare RS, Sabatelli FJ, and the Ziracin susceptibility testing group. In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. J. Antimicrob. Chemother. 47, 15–25 (2001).
   PubMedGoogle Scholar
• Suh YG, Shin DY, Min KH, Hyun SS, Jung JK, Seo SY. Facile construction of the oxaphenalene skeleton by peri ring closore. Formal synthesis of mansonone F. Chem. Commun. 1203–1204 (2000).
   Web of Science ®Google Scholar
• Shin DY, Kim SN, Chae JH et al. Syntheses and anti-MRSA activities of the C3 analogs of mansonone F, a potent anti-bacterial sesquiterpenoid: insights into its structural requirements for anti-MRSA activity. Bioorg. Med. Chem. Lett. 14, 4519–4523 (2004).
   PubMedGoogle Scholar
• Sol V, Branland P, Chaleix V et al. Amino porphyrins as photoinhibitors of Gram-positive and -negative bacteria. Bioorg. Med. Chem. Lett. 14, 4207–4211 (2004).
   PubMed Web of Science ®Google Scholar
• Oliva B, Miller K, Caggiano N et al. Biological properties of novel antistaphylococcal quinoline–indole agents. Antimicrob. Agents Chemother. 47, 458–466 (2003).
   PubMedGoogle Scholar
• Stier MA, Watson BM, Domagala JM et al. The synthesis and SAR of a series of 2-hydroxyisoquinolones, new antibacterial gyrase inhibitors. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (2000).
   Google Scholar
• Tran TP, Ellsworth EL, Stier MA et al. Synthesis and structural–activity relationships of 3-hydroxyquinazoline-2,4-dione antibacterial agents. Bioorg. Med. Chem. Lett. 14, 4405–4409 (2004).
   PubMed Web of Science ®Google Scholar
• Howard JM, Morris CM, Grinius L et al. Using membrane activity to determine the fate of signal peptidase inhibitors with antibacterial properties. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Grinius L, Morris CM, Curnow AW et al. Identification and characterization of new signal peptidase inhibitors among 5S-penem. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Snyder LB, Meng Z, Mate R et al. Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials. Bioorg. Med. Chem. Lett. 14, 4735–4739 (2004).
   PubMed Web of Science ®Google Scholar
• Sharma P, Rane N, Gurram VK. Synthesis and QSAR studies of pyrimido[4,5-d]pyrimidine-2,5-dione derivatives as potential antimicrobial agents. Bioorg. Med. Chem. Lett. 14, 4185–4190 (2004).
   PubMed Web of Science ®Google Scholar
• Hu W, Bürli RW, Kaizerman JA et al. DNA binding ligands with improved in vitro and in vivo potency against drug-resistant Staphlococcus aureus. J. Med. Chem. 47, 4352–4355 (2004).
   PubMed Web of Science ®Google Scholar
• Liehr S, Hansen E, Khorlin A et al. A new family of DNA targeting compounds have potent activity against vancomycin-resistant enterococci and methicillin-resistant S. aureus. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Li J, Chen G, Webster JM. Nematophin, a novel antimicrobial substance produced by Xenorhabdus nematophilus (Enterobactereaceae). Can. J. Microbiol. 43, 770–773 (1997).
   PubMedGoogle Scholar
• Li J, Chen G, Webster JM. Synthesis and anti-staphylococcal activity of nematophin and its analogs. Bioorg. Med. Chem. Lett. 7, 1379–1352 (1997).
   Google Scholar
• Kennedy G, Viziano M, Winders JA et al. Studies on the novel anti-staphylococcal compound nematophin. Bioorg. Med. Chem. Lett. 10, 1751–1754 (2000).
   PubMedGoogle Scholar
• Himmler T, Pirro F, Schmeer N. Synthesis and antibacterial in vitro activity of novel analogues of nematophin. Bioorg. Med. Chem. Lett. 8, 2045–2050 (1998).
   PubMedGoogle Scholar
• Yao S, Sgarbi PW, Marby KA et al. Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. Bioorg. Med. Chem. Lett. 14, 3733–3738 (2004).
   PubMed Web of Science ®Google Scholar
• Wang J, Li J, Czyryca PG, Chang H, Kao J, Chang CW. Synthesis of an unusual branched-chain sugar, 5-C-methyl-l-idopyranose for SAR studies of pyranmycins: implication for the future design of aminoglycoside antibiotics. Bioorg. Med. Chem. Lett. 14, 4389–4393 (2004).
   PubMedGoogle Scholar
• Tsushima M, Iwamatsu K, Tamura A, Shibahara S. Novel cephalosporin derivatives possessing a bicyclic heterocycle at the 3-position. Part I: synthesis and biological activities of 3-(benzothiazol-2-yl)thiocephalosporin derivatives, CP0467 and related compounds. Bioorg. Med. Chem. 6, 1009–1017 (1998).
   PubMedGoogle Scholar
• Ternansky RJ, Draheim SE, Pike AJ et al. Discovery and structure–activity relationship of a series of 1-carba-1-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus. J. Med. Chem. 36, 1971–1976 (1993).
   PubMed Web of Science ®Google Scholar
• Shinagawa H, Yamaga H, Houchigai H, Sumita Y, Sunagawa M. Synthesis and biological properties of a new series of anti-MRSA β-lactams 2-(thiazol-2-ylthio) carbapenems. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (2000).
   Google Scholar
• Ratcliffe RW, Wilkening RR, Wildonger KJ et al. Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392. Bioorg. Med. Chem. Lett. 9, 679–684 (1999).
   PubMed Web of Science ®Google Scholar
• Bryskier A, Aszodi J, Chantot JF. Parenteral cephalosporin classification. Expert Opin. Investig. Drugs 3, 145–171 (1994).
   Google Scholar
• Ishikawa T, Matsunaga N, Tawada H et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg. Med. Chem. Lett. 11, 2427–2437 (2003).
   Google Scholar
• Kasai M, Hatano S, Kitagawa M et al. AS-924, a novel orally active bifunctional prodrug of ceftizoxime. Synthesis and relationship between physicochemical properties and oral absorption. Chem. Pharm. Bull. 47, 1081–1088 (1999).
   PubMedGoogle Scholar
• Ishikawa T, Nakayama Y, Tomimoto M et al. Studies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parental administration. J. Antibiot. 54, 364–374 (2001).
   PubMed Web of Science ®Google Scholar
• Fujimura T, Yamano Y, Yoshida I, Shimada J, Kuwahara S. In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 47, 923–931 (2003).
   PubMed Web of Science ®Google Scholar
• Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50, 915–922 (2002).
   PubMed Web of Science ®Google Scholar
• Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MG, Then RL. In vitro and in vivo properties of Ro 63– 9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45, 825–836 (2001).
   Google Scholar
• Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46, 171–177 (2002).
   PubMed Web of Science ®Google Scholar
• Springer DM, Luh BY, Bronson JJ. Anti-MRSA cephems. Part 1: C-3 substituted thiopyridinium derivatives. Bioorg. Med. Chem. Lett. 11, 797–801 (2001).
   PubMed Web of Science ®Google Scholar
• Springer DM, Luh BY, Goodrich JT, Bronson JJ. Anti-MRSA cephems. Part 2: C-7 cinnamic acid derivatives. Bioorg. Med. Chem. Lett. 11, 265–279 (2003).
   Google Scholar
• Springer DM, Luh BY, Goodrich JT, Bronson JJ. Anti-MRSA cephems. Part 3: additional C-7 acid derivatives. Bioorg. Med. Chem. Lett. 11, 281–291 (2003).
   Google Scholar
• Fung-Tomc JC, Clark J, Minassian B et al. In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci. Antimicrob. Agents Chemother. 46, 971–976 (2002).
   PubMed Web of Science ®Google Scholar
• Cho A, Glinka TW, Ludwikow M, Fan AT, Wang M, Hecker SJ. New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position. Bioorg. Med. Chem. Lett. 11, 137–140 (2001).
   PubMedGoogle Scholar
• Johnson AP, Warner M, Carter M, Livermore DM. In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant Gram-positive cocci. Antimicrob. Agents Chemother. 46, 321–326 (2002).
   PubMed Web of Science ®Google Scholar
• Griffith DC, Harford L, Williams R, Lee VJ, Dudley MN. In vivo antibacterial activity of RWJ-54428, a new cephalosporin with activity against Gram-positive bacteria. Antimicrob. Agents Chemother. 47, 43–47 (2003).
   PubMed Web of Science ®Google Scholar
• Glinka T, Huie K, Cho A et al. Relationships between structure, antibacterial activity, serum stability, pharmacokinetics and efficacy in 3-(heteroarylthio)cephems. Discovery of RWJ-333441 (MC-04,546). Bioorg. Med. Chem. 11, 591–600 (2003).
   PubMed Web of Science ®Google Scholar
• Hecker SJ, Calkins T, Price ME et al. Prodrugs of cephalosporin RWJ-333441 (MC-04,546) with improved aqueous solubility. Antimicrob. Agents Chemother. 47, 2043–2046 (2003).
   PubMed Web of Science ®Google Scholar
• Alexander J, Bindra DS, Glass JD et al. Investigation of (oxodioxolenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral amines. J. Med. Chem. 39, 480–486 (1996).
   PubMed Web of Science ®Google Scholar
• Bush K, Abbanat D, Davies T et al. In vitro and in vivo antibacterial activity of RWJ 442831, a prodrug of the anti-MRSA cephalosporin RWJ 4428. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2003).
   Google Scholar
• Hanaki H, Akagi H, Masaru Y, Otani T, Hyodo A, Hiramatsu K. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 39, 1120–1126 (1995).
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Tamaoka H, Ishikawa H, Kikuchi M. In vitro and in vivo antibacterial activities of OPC-20011, a novel parenteral broad-spectrum 2-oxaisocephem antibiotic. Antimicrob. Agents Chemother. 42, 2943–2949 (1998).
   PubMedGoogle Scholar
• Ascher G, Heilmayer N, Hildebrandt J, Wieser J. Synthesis and SAR of novel cephalosporin – azomethines, broad spectrum antibacterial with anti-MRSA activity. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2003).
   Google Scholar
• Draghi DC, Thorsberry C, Jones ME, Flamm RK, Sahm DF, Karlowsky JA. In vitro activity of CB 181963 against 1064 Gram-positive and Gram-negative pathogens. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2003).
   Google Scholar
• Ishikawa T, Kamiyama K, Nakayama Y, Iizawa Y, Okonogi K, Miyake A. Studies on anti-MRSA parenteral cephalosporins. III. Synthesis and antibacterial activity of 7beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido-3. J. Antibiot. 54, 257–277 (2001).
   PubMed Web of Science ®Google Scholar
• Hanaki H, Nomura S, Akagi H, Hiramatsu K. Improvement of water-soluble cephalosporin derivatives having antibacterial activity against methicillin-resistant Staphylococcus aureus. Chemotherapy 47, 170–176 (2001).
   PubMed Web of Science ®Google Scholar
• Joo HY, Bu SC, Shin JE et al. The in vivo efficacy and pharmacokinetics of LB 11058, a new parenteral cephalosporin in experimental animals. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Cho YR, Kim MJ, Joo HR, Kim HS, Youn H. The in vitro activity of LB 11058, a new parenteral cephalosporin with activity against multi-resistant Gram-positive bacteria. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Chen Z, White RE, Laughlin KJ et al. Discovery of 3-dithiocarbamoylcephalosporins highly active in vitro against resistant Gram-positive bacteria. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (2000).
   Google Scholar
• Laub JB, Greenlee ML, DiNinno F, Hüber JL, Sundelof JG. The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems. Bioorg. Med. Chem. Lett. 9, 2973–2976 (1999).
   PubMed Web of Science ®Google Scholar
• Miller RA, Humphrey GR, Lieberman DR et al. A practical and efficient preparation of the releasable naphthosultam side chain of a novel anti-MRSA carbapenem. J. Organ. Chem. 65, 1399–1406 (2000).
   PubMed Web of Science ®Google Scholar
• Imamura H, Ohtake N, Jona H et al. Dicationic dithiocarbamate carbapenems with anti-MRSA activity. Bioorg. Med. Chem. 9, 1571–1578 (2001).
   PubMed Web of Science ®Google Scholar
• Ohtake N, Imamura H, Jona H et al. Novel dithiocarbamate carbapenems with anti-MRSA activity. Bioorg. Med. Chem. 6, 1089– 1101 (1998).
   PubMed Web of Science ®Google Scholar
• Nagano R, Shibata K, Adachi Y, Imamura H, Hashizume T, Morishima H. In vitro activities of novel trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44, 489–495 (2000).
   PubMed Web of Science ®Google Scholar
• Oh CH, Lee SC, Cho JH. Synthesis and biological activity of 1 β-methyl-2-[5-(2-N-substituted aminoethylcarbamoyl)pyrrolidin-3-ylthio]carbapenem derivatives. Eur. Med. Chem. 38, 841–850 (2003).
   PubMed Web of Science ®Google Scholar
• Hattori K, Yamada A, Kuroda S, Chiba T, Murata M, Sakane K. Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems. Bioorg. Med. Chem. Lett. 12, 383–386 (2002).
   PubMedGoogle Scholar
• Oh CH, Cho JH, Lee SC. Synthesis and biological activities of 1β-methyl carbapenems having oxime and imine moieties. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2003).
   Google Scholar
• Fukuoka T, Ohya S, Utsui Y et al. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem. Antimicrob. Agents Chemother. 41, 2652–2663 (1997).
   PubMed Web of Science ®Google Scholar
• Shitara E, Yamamoto Y, Kano Y et al. CP 5068, a new carbapenem, synthesis and structure activity relationships. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (2000).
   Google Scholar
• Ida T, Kurazono J, Nagura J et al. CP 5068, a new carbapenem, in vitro and in vivo activities against MRSA. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (2000).
   Google Scholar
• Nieuwlandt D, Kellogg E, Wecker M et al. Anti-MRSA drug leads from evolutionary chemistry. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Aceto MD, Harris LS, Lesher GY, Pearl J, Brown TG Jr. Pharmacologic studies with 7-benzyl-1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid. J. Pharmacol. Exp. Ther. 158(2), 286–293 (1967).
   PubMedGoogle Scholar
• Tabart M, Picaut G, Desconclois JF, Dutka-Malen S, Huet Y, Berthaud N. Synthesis and biological evaluation of benzo[b]naphthyridones, a series of new topical antibacterial agents. Bioorg. Med. Chem. Lett. 11, 919–921 (2001).
   Google Scholar
• Tabart M, Picaut G, Lavergne M et al. Benzo[f]naphtyridones: a new family of topical antibacterial agents active on multi-resistant Gram-positive pathogens. Bioorg. Med. Chem. Lett. 13, 1329–1331 (2003).
   PubMedGoogle Scholar
• Kavanagh F, Hervey A, Robbins WJ. Antibiotic substances from basidiomycetes – VIII. Pleurotus multilus and Pleurotus parseckreanus pilat. Proc. Natl Acad. Sci. USA 37, 570–574 (1951).
   PubMed Web of Science ®Google Scholar
• Rittenhouse S, Moore T, Donald B, Hunt E, Woodnutt G. In vitro activity of two novel pleuromutilin derivatives, SB-247386 and SB-268091. Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (1999).
   Google Scholar
• Berry V, Satterfield J, Singley C, Hunt E, Woodnutt G. In vivo efficacy of the novel topical pleuromutilins, SB-247386 and SB-268091. Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy CA, USA (1999).
   Google Scholar
• Cutler BR, Cutler SJ, Josling PD, Wilson P. Activity of a novel, stable, allicin extract in liquid and cream formulations, against methicillin-resistant S. aureus including mupirocin-resistant MRSA. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2001).
   Google Scholar
• Chatterjee S, Chatterjee S, Lad SJ et al. Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization. J. Antibiot. (Tokyo) 45(6), 832–838 (1992).
   PubMedGoogle Scholar
• Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, Ljungh A. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 54, 648–653 (2004).
   PubMed Web of Science ®Google Scholar
• Vazifeh D, Abdelghaffar H, Labro MT. Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin. Antimicrob. Agents Chemother. 46, 1364–1374 (2002).
   PubMed Web of Science ®Google Scholar
• Otani T, Tanaka M, Ito E et al. In vitro and in vivo antibacterial activity of DK-505k, a novel fluoroquinolone. Antimicrob. Agents Chemother. 47, 3750–3759 (2003).
   PubMed Web of Science ®Google Scholar
• Jones ME, Klootwijk M, Schmitz FJ, Verhoef J. Comparative activity of quinolones compounds moxiflonxacin, grepafloxacin, trovafloxacin, levofloxacin, sparfloxacin, ofloxacin and oxazolidinone, linezolid against unrelated clinical isolates of ciprofloxacin-resistant and sensitive S. aureus. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002).
   Google Scholar
• Tanaka M, Yamazaki E, Chiba M et al. In vitro antibacterial activities of DQ-113, a potent quinolone against clinical isolates. Antimicrob. Agents Chemother. 46, 904–908 (2002).
   PubMed Web of Science ®Google Scholar
• Choi KH, Hong JS, Kim SK, Lee DK, Yoon SJ, Choi EC. In vitro and in vivo activities of DW-116 a new fluoroquinolone. J. Antimicrob. Chemother. 39, 509–514 (1997).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Bajaksouzian S, Windau A et al. In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob. Agents Chemother. 48, 3338–3342 (2004).
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Yanagihara K, Miyazaki Y et al. Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice. Antimicrob. Agents Chemother. 47(12), 3694–3698 (2003).
   PubMedGoogle Scholar
• Barry AL. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents. Antimicrob. Agents Chemother. 32, 150–152 (1988).
   Google Scholar
• Gravestock MB, Acton DG, Betts MJ et al. New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains. Bioorg. Med. Chem. Lett. 13, 4179–4186 (2003).
   PubMedGoogle Scholar
• Howe RA, Wootton M, Noel AR, Bowker KE, Walsh TR, MacGowan AP. Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid. Antimicrob. Agents Chemother. 47, 3651–3652 (2003).
   PubMedGoogle Scholar
• Anderegg TR, Biedenbach DJ, Jones RN. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. Antimicrob. Agents Chemother. 46, 2662–2664 (2002).
   PubMed Web of Science ®Google Scholar
• Lee JS, Cho YS, Chang MH, Koh HY, Chung BY, Pae AN. Synthesis and in vitro activity of novel isoxazolyl tetrahydropyridinyl oxazolidinone antibacterial agents. Bioorg. Med. Chem. Lett. 13, 4117–4120 (2003).
   PubMed Web of Science ®Google Scholar
• Thomasco LM, Gadwood RC, Weaver EA et al. The synthesis and antibacterial activity of 1,3,4-thiadiazole phenyl oxazolidinone analogues. Bioorg. Med. Chem. Lett. 13, 4193–4196 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson PD, Aristoff PA, Zurenko GE et al. Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials. Bioorg. Med. Chem. Lett. 13, 4197–4200 (2003).
   PubMed Web of Science ®Google Scholar
• Singh U, Raju B, Lam S et al. New antibacterial tetrahydro-4(2H)-thiopyran and thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones. Bioorg. Med. Chem. Lett. 13, 4209–4212 (2003).
   PubMed Web of Science ®Google Scholar
• Ried B, Endermann R. Recent developments with oxazolidinone antibiotics. Expert Opin. Ther. Patents 9, 625–633 (1996).
   Google Scholar
• Endermann R, Bartel S, Guarnieri W et al. Synthesis and antibacterial activity of novel hetero aryl oxazolidinones. III. Activities against clinically important Gram-positive pathogens. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (1998).
   Google Scholar
• Bartel S, Endermann R, Guarnieri W et al. Synthesis and antibacterial activity of novel hetero aryl oxazolidinones. I. Benzoxazone and benzothiazole oxazolidinones. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (1998).
   Google Scholar
• Locher HH, Specklin JL, Borner Y et al. Synthesis and antibacterial action of novel quinolone-linked oxazolidinones. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002).
   Google Scholar
• Hackbarth CJ, Chen DZ, Lewis JG et al. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46, 2752–2764 (2002).
   PubMed Web of Science ®Google Scholar
• Margolis PS, Hackbarth CJ, Young DC et al. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. 44, 1825–1831 (2000).
   PubMed Web of Science ®Google Scholar
• Jones RN, Fritsche TR, Sader HS. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Diagn. Microbiol. Infect. Dis. 49, 63–65 (2004).
   PubMed Web of Science ®Google Scholar
• Lofland D, Difuntorum S, Waller A et al. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J. Antimicrob. Chemother. 53, 664–666 (2004).
   PubMed Web of Science ®Google Scholar
• Wademan SN, Almstetter M, Borer Y et al. Identification of potent inhibitors of the Staphylococcus aureus methionine aminopeptidase. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, IL, USA (2003).
   Google Scholar